Geode Capital Management LLC Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Geode Capital Management LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 2.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 120,589,782 shares of the biopharmaceutical company’s stock after buying an additional 2,923,537 shares during the quarter. Geode Capital Management LLC’s holdings in Pfizer were worth $3,190,131,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the 4th quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer during the 4th quarter worth about $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer in the fourth quarter valued at about $28,000. Noble Wealth Management PBC purchased a new stake in Pfizer in the fourth quarter valued at approximately $31,000. Finally, Curio Wealth LLC acquired a new stake in Pfizer during the 4th quarter valued at approximately $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the topic of a number of recent research reports. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Citigroup dropped their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Truist Financial dropped their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Finally, Bank of America restated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Price Performance

PFE stock opened at $25.36 on Tuesday. The business has a 50 day simple moving average of $26.05 and a 200-day simple moving average of $26.88. The firm has a market capitalization of $143.80 billion, a PE ratio of 17.98, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue was up 24.7% compared to the same quarter last year. During the same period last year, the business earned $0.10 earnings per share. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.